Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00223249 · ClinicalTrials.gov registry record · Phase 4
Quetiapine in Patients With Bipolar and Alcohol Abuse/Dependence
A Phase 4 study of Bipolar Disorder and Alcohol Abuse/Dependence, sponsored by University of Texas Southwestern Medical Center.
- Completed
- Registry status
- Phase 4
- Development phase
- 115
- Enrollment target
- 1
- Study location
NCT00223249: Completed Phase 4 study of Bipolar Disorder and Alcohol Abuse/Dependence, sponsored by University of Texas Southwestern Medical Center.
NCT00223249 is a Phase 4 study of Bipolar Disorder and Alcohol Abuse/Dependence that has completed, run by University of Texas Southwestern Medical Center. The registered enrollment target is 115 participants, below the 332-participant average among 162 other Bipolar Disorder trials with a reported enrollment target (65% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00223249, a Phase 4 study of Bipolar Disorder and Alcohol Abuse/Dependence, has completed, sponsored by University of Texas Southwestern Medical Center.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 115 participants
- Enrollment target
- 1
- Study location
Study Summary
The abuse of alcohol is especially common in people with bipolar disorder. However, very little is known about the pharmacotherapy of people with both bipolar disorder and alcohol abuse/dependence. The purpose of this study is to determine if alcohol use and cravings are decreased with quetiapine add-on therapy compared to placebo and to determine if quetiapine add-on therapy is associated with greater improvement in mood, impulsivity, functioning and decreased alcohol use than placebo.
Conditions Studied
Interventions
- DRUG Quetiapine
Study Locations (1)
Texas
- The UT Southwestern Medical Center at Dallas - Dallas
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 115 participants |
| Start Date | 2002-11 |
| Est. Completion | 2004-08 |
| Phase | Phase 4 |
What the finished NCT00223249 record still lists
NCT00223249 is an interventional study that assigns participants to a tested intervention. The registered 115 participants enrollment target is mid-sized for trials with a published cap, below the 332-participant average among 162 other Bipolar Disorder trials with a reported enrollment target (65% lower).
The record links to 2 conditions, with Bipolar Disorder appearing as the primary indexed condition, and to 1 intervention - of which Quetiapine is the first listed.
NCT00223249 reports a single indexed study location in Texas.
Frequently Asked Questions
What is clinical trial NCT00223249 about?
NCT00223249 is a clinical study titled "Quetiapine in Patients With Bipolar and Alcohol Abuse/Dependence". The abuse of alcohol is especially common in people with bipolar disorder. However, very little is known about the pharmacotherapy of people with both bipolar disorder and alcohol abuse/dependence. The purpose of this study is to determine if alcohol use and cravings are decreased with quetiapine ad...
What is the current status of trial NCT00223249?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 115 participants. The study started on 2002-11. Estimated completion is 2004-08.
What conditions does trial NCT00223249 study?
This clinical trial studies the following conditions: Bipolar Disorder, Alcohol Abuse/Dependence.
What interventions are being tested in trial NCT00223249?
The interventions under investigation include: Quetiapine (DRUG).
Who is sponsoring clinical trial NCT00223249?
This trial is sponsored by University of Texas Southwestern Medical Center, which has 837 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00223249 being conducted?
This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Bipolar Disorder
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00223249's enrollment target sits among peer trials
115 60th of 162 higher than 103 of 162 other Bipolar Disorder trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Bipolar Disorder trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study to Evaluate the Effectiveness of Valbenazine in Adult Participants With Tardive Dyskinesia (TD) Who Remain Symptomatic While Receiving or After Stopping a Vesicular Monoamine Transporter 2 (VMAT2) Inhibitor
RECRUITING · Phase 4
-
FMRI Study of Brain Response Before and After Lithium Treatment in People With Bipolar Disorder
COMPLETED · Phase 4
-
Treatment of Geriatric Bipolar Mood Disorders: A Pilot Study
COMPLETED · Phase 4
-
Treatment With Quetiapine for Youth With Substance Use Disorders and Severe Mood Dysregulation
COMPLETED · Phase 4
-
Lamictal As Add on Treatment in Mixed States of Bipolar Disorder
COMPLETED · Phase 4
-
Ziprasidone in Bipolar Disorder With Comorbid Lifetime Panic or Generalized Anxiety Disorder(GAD)
COMPLETED · Phase 4
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02346929 · 115 participants · NA
Hematoma Block for Distal Radius Fracture
- NCT03394365 · 115 participants · Phase 3
A Phase 3 Study of Tabelecleucel for Participants With Epstein-Barr Virus-Associated Post-Transplant Lymphoproliferative Disease After Failure With Rituximab or Rituximab and Chemotherapy
- NCT03907475 · 115 participants · Phase 2
Durvalumab in Combination With Chemotherapy in Treating Patients With Advanced Solid Tumors, DURVA+ Trial
- NCT05086692 · 115 participants · Phase 1
A Beta-only IL-2 ImmunoTherapY Study
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia